EAST NORRITON, Pa., March 18, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Friday, March 25, 2011 at 8:30 a.m. EDT to provide a business update and discuss its fourth quarter 2010 financial results.
To participate in the call, please dial 1-888-680-0879 (domestic) or 1-617-213-4856 (international) and reference access code 55045101.
This conference call will also be webcast live and can be accessed from the Investors section of the Company's website at http://www.tengion.com or at https://www.theconferencingservice.com/prereg/key.process?key=PXR36H93C. The webcast will be archived on the website until April 25, 2011.
Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney
|SOURCE Tengion, Inc.|
Copyright©2010 PR Newswire.
All rights reserved